Emergent Biosolutions (EBS) 27.64 $EBS
Doug Loe: Canada Has Earned Its Spot In The Biotech All-Star Team Photo
Life Sciences Report - Seeking Alpha - Fri Dec 19, 9:53AM CST
Biotech investors in the United States who overlook investment opportunities across the borders are missing out on huge opportunities, says Douglas Loe, healthcare equity analyst with Euro Pacific Canada. In this interview with The Life Sciences...
BIIB: 340.89 (+5.13), VRX: 140.33 (-0.22), QLTI: 3.72 (+0.08), CTRX: 51.83 (+0.14), BCRX: 11.83 (+0.76), ACT: 254.20 (-1.68), MDT: 74.08 (+0.31), TKMR: 13.97 (+0.14), NEPT: 1.88 (+0.03), BSX: 13.13 (+0.07), AGN: 210.12 (+0.95), CMRX: 36.80 (+0.70), ALNY: 93.52 (+0.97), SRPT: 13.88 (+0.47), SHPG: 209.29 (+0.07), NLNK: 39.08 (+1.36), SNY: 46.35 (+0.50), MSLI: 1.67 (+0.02), NVCN: 6.60 (unch), CRME: 8.56 (+0.06), EBS: 27.64 (+1.28), GSK: 42.85 (+0.11), CELG: 109.60 (+3.48), GILD: 91.29 (+1.84), MRK: 57.46 (+0.25), NVDQ: 16.90 (+0.55), NVS: 93.91 (+0.66)
Uptrend Call Working As Emergent Biosolutions Stock Rises 16.6% (EBS)
Comtex SmarTrend(R) - Fri Dec 19, 9:48AM CST
SmarTrend identified an Uptrend for Emergent Biosolutions (NYSE:EBS) on October 31st, 2014 at $23.06. In approximately 2 months, Emergent Biosolutions has returned 16.63% as of today's recent price of $26.89.
EBS: 27.64 (+1.28)
Emergent BioSolutions Buys EV-035 Series from Evolva - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Dec 18, 3:45PM CST
Emergent BioSolutions Inc. announced that it has entered into an agreement with Evolva Holding for acquiring the latter's anti-bacterial program.
ACT: 254.20 (-1.68), VRX: 140.33 (-0.22), EBS: 27.64 (+1.28), SCMP: 13.75 (+0.44)
Evolva disposes EV-035 series programme to Emergent BioSolutions
M2 - Thu Dec 18, 4:59AM CST
Evolva Holding SA (SIX:EVE), a health, wellness and nutrition company, announced on Wednesday the acquisition by Emergent BioSolutions Inc (NYSE:EBS) of Evolva's anti-bacterial programme, the EV-035 series.
EBS: 27.64 (+1.28)
Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2014
M2 - Thu Dec 18, 3:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/dsgsvz/chronic) has announced the addition of the "Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Lymphocytic Leukemia (CLL), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Lymphocytic Leukemia (CLL) and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Chronic Lymphocytic Leukemia (CLL) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Chronic Lymphocytic Leukemia (CLL) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Bristol-Myers Squibb Company - F. Hoffmann-La Roche Ltd. - Amgen Inc. - Sanofi - Eli Lilly and Company - Viralytics Ltd. - Genentech, Inc. - MedImmune, LLC - Gilead Sciences, Inc. - Daiichi Sankyo Company, Limited - Emergent BioSolutions Inc. - Lentigen Corporation - Amorfix Life Sciences Ltd. - Piramal Enterprises Limited - Celltrion, Inc. - Astellas Pharma Inc. - BioMarin Pharmaceutical Inc. - Richter Gedeon Nyrt. - Astex Pharmaceuticals, Inc. - Genmab A/S - Cyclacel Pharmaceuticals Inc. - Celgene Corporation - Onyx Pharmaceuticals, Inc. - Bayer AG - Incyte Corporation - Merck KGaA - 4SC AG - Celldex Therapeutics, Inc. - Immunomedics, Inc. - TG Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/dsgsvz/chronic
BMRN: 88.18 (+0.89), CLDX: 17.08 (-0.18), CYCC: 0.69 (+0.01), IMMU: 4.41 (+0.13), EBS: 27.64 (+1.28), INCY: 71.57 (+1.99), TGTX: 16.03 (+0.33), AMGN: 160.67 (+3.15), LLY: 70.16 (+0.42), BMY: 59.15 (-0.01), GILD: 91.29 (+1.84), CELGZ: 3.34 (-0.01)
Emergent BioSolutions Expands Biodefense Franchise; Acquires Portfolio of Broad Spectrum Antibiotics
GlobeNewswire - Wed Dec 17, 6:00AM CST
-- Lead antibiotic candidate currently under DTRA development contract, valued at up to $15 million, as an oral and IV treatment for Burkholderia pseudomallei as well as other bioterror agents
EBS: 27.64 (+1.28)
Evolva Sells EV-035 Series to Emergent BioSolutions
Business Wire - Wed Dec 17, 12:01AM CST
Evolva Holding SA ("Evolva", SIX:EVE) today announced that Emergent BioSolutions Inc. ("Emergent", NYSE:EBS) has acquired Evolva's anti-bacterial programme, the EV-035 series. The lead compound in the EV-035 series is the broad-spectrum antibiotic GC-072, which is being developed with US government biodefense funding. For Evolva, this transaction is worth up to USD 70.5 million plus royalties.
EBS: 27.64 (+1.28)
United States Vaccines, Skin Replacement Products and Biologicals Manufacturing Industry Analytics 2014-2021 - Market to reach $39.5 billion by 2021
M2 - Mon Dec 15, 8:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/s847lc/vaccines_skin) has announced the addition of Plunkett Research Ltd's new report "Vaccines, Skin Replacement Products and Biologicals Manufacturing Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2021" to their offering. Vaccines, Skin Replacement Products and Biologicals Manufacturing Industry (U.S.) to reach $39.5 billion by 2021 Vital industry-specific data including metrics, benchmarks, historic numbers, growth rates and forecasts that will save countless hours of research. Core Benefits to Customer: 1. Comprehensive overview of an industry's financial results, ratios, vital statistics and metrics in one package 2. Complete benchmarking of the industry and its top companies 3. Deep industry and company financials This Report Features: 1. Historical data 2. Revenue forecasts, growth rates and CAGR 3. Operating ratios 4. Complete data for benchmarking a company to its industry and to specific leading companies 5. Benchmarking this industry to all U.S. industries 6. Deep profiles and financial histories/operating ratios for up to ten top U.S.-based companies Designed to benefit: - Analysis and Financial Modeling - Investment Professionals - Lenders - M&A Advisors - Appraisers - Consultants Key Data: Industry Summary - Revenues historical through 2013 - Revenues projected through 2021 - Employee Count 2007-2013 - Annual Growth Rate 2013 - CAGR 2006 through 2013 - CAGR 2014 through 2021 - Top U.S. Companies Employment and Establishments - Number of Firms 2007-2013 - Number of Establishments 2007-2013 - Employees, 2007-2013 - Average Annual Sales per Firm & per Establishment 2007-2013 - Sales per Employee Average Annual Operating Ratios - Revenue Compared to All Industries - Expenses Compared to All Industries - Profits & Income Taxes Compared to All Industries Benchmarks This Industry Compared to All Industries - Comparison of Revenues, Profits and Taxes to All Industries Industry Results, Publicly-Held Companies (U.S.), Average for all Companies - Industry Income Statement, Balance Sheet, Cash Flow Statement, 2008-2013 Top Companies Profiled & Ranked - Anika Therapeutics Inc - CSL Behring LLC - Emergent BioSolutions Inc - Halozyme Therapeutics Inc - LifeCell Corporation - Lifecore Biomedical Inc - MiMedx Group Inc - Organogenesis Inc - RTI Biologics Inc - Zoetis Inc For more information visit http://www.researchandmarkets.com/research/s8...cines_skin Source: Plunkett Research Ltd
ZTS: 43.84 (+0.87), RTIX: 5.20 (unch), HALO: 9.34 (+0.31), EBS: 27.64 (+1.28), ANIK: 38.26 (+0.73), MDXG: 11.17 (+0.17)
InsiderInsights.com Daily Round Up 12/11/14: VRX, NS, PSEC, PSX
InsiderInsights - at Seeking Alpha - Thu Dec 11, 11:10PM CST
AMBA: 52.05 (+0.72), PSX: 72.10 (-0.46), CCI: 79.05 (-0.13), VRX: 140.33 (-0.22), RAX: 48.24 (+0.45), SLRC: 18.01 (-0.02), DOOR: 60.04 (-0.10), EBS: 27.64 (+1.28), MMI: 33.68 (+0.05), RLYP: 30.35 (-0.22), FCX: 22.91 (+0.07), NS: 57.17 (+0.24), TTGT: 10.67 (-0.01), GHC: 877.19 (-0.76), WIW: 11.28 (+0.03), ADI: 56.71 (+0.05), HBI: 110.93 (-0.07), SAEX: 4.60 (+0.05), FOXF: 16.15 (+0.07), PSEC: 8.59 (-0.02)
Anthrax - Pipeline Review, H1 2014
M2 - Wed Dec 03, 7:33AM CST
Research and Markets (http://www.researchandmarkets.com/research/gq3s59/anthrax) has announced the addition of the "Anthrax - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Anthrax, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Anthrax and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Anthrax - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Anthrax pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Aradigm - Bavarian Nordic - Bristol-Myers Squibb - Cellceutix - Conkwest - ContraFect - Elusys - Emergent BioSolutions - Evolva - Green Cross - Grifols - Hawaii Biotech - Immunovaccine - Innovative Biologics - MacroGenics - Microbiotix - NanoBio - Navigen - Oragenics - PaxVax - Pfenex - Planet Biotechnology - ProThera Biologics - Protein Potential - PsiOxus - Revivicor - SelectX - Soligenix - Summit - Tetraphase - The Medicines - Vaxin - iBio For more information visit http://www.researchandmarkets.com/research/gq3s59/anthrax
EBS: 27.64 (+1.28), BMY: 59.15 (-0.01)
3 Fast-Growing Biotech Stocks To Buy in December
Todd Campbell, The Motley Fool - Motley Fool - Mon Nov 24, 9:46AM CST
Year end is coming up quickly, and that has investors pouring over portfolios, dissecting financial reports, and considering names to own heading into 2015. With that in mind, read on to learn why I think these three biotech stocks may prove...
INSY: 41.52 (+0.51), EBS: 27.64 (+1.28), CBST: 100.29 (-0.09)
Emergent Biosolutions Earnings Hindsight: Up 9.2% in Last 18 Days (EBS)
Comtex SmarTrend(R) - Mon Nov 24, 8:16AM CST
18 days ago, on November 6th, 2014, Emergent Biosolutions (NYSE:EBS) reported its earnings. Analysts, on average, expected earnings of $0.47 per share on sales of $127.0 million. The company actually reported EPS of $0.50 on sales of $138.0 million, beating EPS estimates by $0.03 and beating revenue estimates by $11.0 million. Shares of Emergent Biosolutions have climbed from $22.49 to $24.56, representing a gain of 9.2% since the company reported earnings 18 days ago.
EBS: 27.64 (+1.28)
Emergent BioSolutions to Webcast Presentation at 25th Annual Oppenheimer Healthcare Conference
GlobeNewswire - Mon Nov 24, 6:00AM CST
Emergent BioSolutions Inc. (NYSE:EBS) announced today that the company will be webcasting its presentation at the 25 Annual Oppenheimer Healthcare Conference in New York on Wednesday, December 10, 2014 at 2:45 PM Eastern. During the presentation, a member of the company's management team will provide a corporate overview, which may include a discussion of the company's recent business developments as well as its most recently reported financial results and guidance. The webcast of this presentation will be available both live and by replay, accessible from the Emergent website www.emergentbiosolutions.com under "Investors."
EBS: 27.64 (+1.28)
Emergent Biosolutions Earnings Hindsight: Up 7.7% in Last 11 Days (EBS)
Comtex SmarTrend(R) - Mon Nov 17, 11:59AM CST
A week ago on November 6th, 2014 Emergent Biosolutions (NYSE:EBS) reported earnings and analysts, on average, expected earnings of $0.47 on sales of $127.0 million. The company actually reported EPS of $0.50 on sales of $138.0 million, beating EPS estimates by $0.03 and beating revenue estimates by $11.0 million. Shares of Emergent Biosolutions have climbed from $22.49 to $24.22, representing a gain of 7.7% since the company reported earnings 11 days ago.
EBS: 27.64 (+1.28)
Worried About a Market Crash? These 3 Stocks Soared During the Great Recession
Todd Campbell, The Motley Fool - Motley Fool - Tue Nov 11, 6:38AM CST
The 7.2% drop in the S&P 500 between mid-September and mid-October was an attention-getting fall that should serve as a wake-up call to investors who may have grown complacent over the past five years, but by historical standards the decline was...
CTRX: 51.83 (+0.14), EBS: 27.64 (+1.28), CMN: 42.07 (+0.40)
Emergent BioSolutions Beats on Q3 Earnings, Guidance Up - Analyst Blog
Lopamudra Bhattacharya - Zacks Investment Research - Mon Nov 10, 11:30AM CST
Emergent BioSolutions reported third quarter earnings of 67 cents per share.
AGN: 210.12 (+0.95), EBS: 27.64 (+1.28), ABAX: 58.48 (+0.22), ABBV: 66.21 (+1.86)
Emergent BioSolutions Seeks Expanded BioThrax Label; Submits FDA Application for Post-Exposure Prophylaxis
GlobeNewswire - Mon Nov 10, 6:07AM CST
Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking to expand the label of BioThrax (Anthrax Vaccine Adsorbed) to include a post-exposure prophylaxis (PEP) indication. BioThrax, the only FDA-licensed vaccine to prevent anthrax disease, is currently licensed for a pre-exposure prophylaxis indication only.
EBS: 27.64 (+1.28)
Emergent Biosolutions posts 3Q profit
Automated Insights - Fri Nov 07, 4:04AM CST
ROCKVILLE, Md. (AP) _ Emergent Biosolutions Inc. (EBS) on Friday reported earnings of $21.8 million in its third quarter.
EBS: 27.64 (+1.28)
Emergent BioSolutions Inc Busts Through Guidance. Sort of.
Brian Orelli, The Motley Fool - Motley Fool - Thu Nov 06, 7:39PM CST
Considering that Emergent BioSolutions has regular government contracts and other manufacturing contracts -- so regular that it's willing to give quarterly guidance, which many companies wouldn't dream of -- it was a little surprising to see by...
EBS: 27.64 (+1.28)
Doug Loe: Canada Has Earned Its Spot In The Biotech All-Star Team Photo
Life Sciences Report - Seeking Alpha - Fri Dec 19, 9:53AM CST
Biotech investors in the United States who overlook investment opportunities across the borders are missing out on huge opportunities, says Douglas Loe, healthcare equity analyst with Euro Pacific Canada. In this interview with The Life Sciences...
BIIB: 340.89 (+5.13), VRX: 140.33 (-0.22), QLTI: 3.72 (+0.08), CTRX: 51.83 (+0.14), BCRX: 11.83 (+0.76), ACT: 254.20 (-1.68), MDT: 74.08 (+0.31), TKMR: 13.97 (+0.14), NEPT: 1.88 (+0.03), BSX: 13.13 (+0.07), AGN: 210.12 (+0.95), CMRX: 36.80 (+0.70), ALNY: 93.52 (+0.97), SRPT: 13.88 (+0.47), SHPG: 209.29 (+0.07), NLNK: 39.08 (+1.36), SNY: 46.35 (+0.50), MSLI: 1.67 (+0.02), NVCN: 6.60 (unch), CRME: 8.56 (+0.06), EBS: 27.64 (+1.28), GSK: 42.85 (+0.11), CELG: 109.60 (+3.48), GILD: 91.29 (+1.84), MRK: 57.46 (+0.25), NVDQ: 16.90 (+0.55), NVS: 93.91 (+0.66)
Uptrend Call Working As Emergent Biosolutions Stock Rises 16.6% (EBS)
Comtex SmarTrend(R) - Fri Dec 19, 9:48AM CST
SmarTrend identified an Uptrend for Emergent Biosolutions (NYSE:EBS) on October 31st, 2014 at $23.06. In approximately 2 months, Emergent Biosolutions has returned 16.63% as of today's recent price of $26.89.
EBS: 27.64 (+1.28)
Emergent BioSolutions Buys EV-035 Series from Evolva - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Dec 18, 3:45PM CST
Emergent BioSolutions Inc. announced that it has entered into an agreement with Evolva Holding for acquiring the latter's anti-bacterial program.
ACT: 254.20 (-1.68), VRX: 140.33 (-0.22), EBS: 27.64 (+1.28), SCMP: 13.75 (+0.44)
Evolva disposes EV-035 series programme to Emergent BioSolutions
M2 - Thu Dec 18, 4:59AM CST
Evolva Holding SA (SIX:EVE), a health, wellness and nutrition company, announced on Wednesday the acquisition by Emergent BioSolutions Inc (NYSE:EBS) of Evolva's anti-bacterial programme, the EV-035 series.
EBS: 27.64 (+1.28)
Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2014
M2 - Thu Dec 18, 3:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/dsgsvz/chronic) has announced the addition of the "Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Lymphocytic Leukemia (CLL), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Lymphocytic Leukemia (CLL) and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Chronic Lymphocytic Leukemia (CLL) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Chronic Lymphocytic Leukemia (CLL) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Bristol-Myers Squibb Company - F. Hoffmann-La Roche Ltd. - Amgen Inc. - Sanofi - Eli Lilly and Company - Viralytics Ltd. - Genentech, Inc. - MedImmune, LLC - Gilead Sciences, Inc. - Daiichi Sankyo Company, Limited - Emergent BioSolutions Inc. - Lentigen Corporation - Amorfix Life Sciences Ltd. - Piramal Enterprises Limited - Celltrion, Inc. - Astellas Pharma Inc. - BioMarin Pharmaceutical Inc. - Richter Gedeon Nyrt. - Astex Pharmaceuticals, Inc. - Genmab A/S - Cyclacel Pharmaceuticals Inc. - Celgene Corporation - Onyx Pharmaceuticals, Inc. - Bayer AG - Incyte Corporation - Merck KGaA - 4SC AG - Celldex Therapeutics, Inc. - Immunomedics, Inc. - TG Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/dsgsvz/chronic
BMRN: 88.18 (+0.89), CLDX: 17.08 (-0.18), CYCC: 0.69 (+0.01), IMMU: 4.41 (+0.13), EBS: 27.64 (+1.28), INCY: 71.57 (+1.99), TGTX: 16.03 (+0.33), AMGN: 160.67 (+3.15), LLY: 70.16 (+0.42), BMY: 59.15 (-0.01), GILD: 91.29 (+1.84), CELGZ: 3.34 (-0.01)
Emergent BioSolutions Expands Biodefense Franchise; Acquires Portfolio of Broad Spectrum Antibiotics
GlobeNewswire - Wed Dec 17, 6:00AM CST
-- Lead antibiotic candidate currently under DTRA development contract, valued at up to $15 million, as an oral and IV treatment for Burkholderia pseudomallei as well as other bioterror agents
EBS: 27.64 (+1.28)
Evolva Sells EV-035 Series to Emergent BioSolutions
Business Wire - Wed Dec 17, 12:01AM CST
Evolva Holding SA ("Evolva", SIX:EVE) today announced that Emergent BioSolutions Inc. ("Emergent", NYSE:EBS) has acquired Evolva's anti-bacterial programme, the EV-035 series. The lead compound in the EV-035 series is the broad-spectrum antibiotic GC-072, which is being developed with US government biodefense funding. For Evolva, this transaction is worth up to USD 70.5 million plus royalties.
EBS: 27.64 (+1.28)
United States Vaccines, Skin Replacement Products and Biologicals Manufacturing Industry Analytics 2014-2021 - Market to reach $39.5 billion by 2021
M2 - Mon Dec 15, 8:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/s847lc/vaccines_skin) has announced the addition of Plunkett Research Ltd's new report "Vaccines, Skin Replacement Products and Biologicals Manufacturing Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2021" to their offering. Vaccines, Skin Replacement Products and Biologicals Manufacturing Industry (U.S.) to reach $39.5 billion by 2021 Vital industry-specific data including metrics, benchmarks, historic numbers, growth rates and forecasts that will save countless hours of research. Core Benefits to Customer: 1. Comprehensive overview of an industry's financial results, ratios, vital statistics and metrics in one package 2. Complete benchmarking of the industry and its top companies 3. Deep industry and company financials This Report Features: 1. Historical data 2. Revenue forecasts, growth rates and CAGR 3. Operating ratios 4. Complete data for benchmarking a company to its industry and to specific leading companies 5. Benchmarking this industry to all U.S. industries 6. Deep profiles and financial histories/operating ratios for up to ten top U.S.-based companies Designed to benefit: - Analysis and Financial Modeling - Investment Professionals - Lenders - M&A Advisors - Appraisers - Consultants Key Data: Industry Summary - Revenues historical through 2013 - Revenues projected through 2021 - Employee Count 2007-2013 - Annual Growth Rate 2013 - CAGR 2006 through 2013 - CAGR 2014 through 2021 - Top U.S. Companies Employment and Establishments - Number of Firms 2007-2013 - Number of Establishments 2007-2013 - Employees, 2007-2013 - Average Annual Sales per Firm & per Establishment 2007-2013 - Sales per Employee Average Annual Operating Ratios - Revenue Compared to All Industries - Expenses Compared to All Industries - Profits & Income Taxes Compared to All Industries Benchmarks This Industry Compared to All Industries - Comparison of Revenues, Profits and Taxes to All Industries Industry Results, Publicly-Held Companies (U.S.), Average for all Companies - Industry Income Statement, Balance Sheet, Cash Flow Statement, 2008-2013 Top Companies Profiled & Ranked - Anika Therapeutics Inc - CSL Behring LLC - Emergent BioSolutions Inc - Halozyme Therapeutics Inc - LifeCell Corporation - Lifecore Biomedical Inc - MiMedx Group Inc - Organogenesis Inc - RTI Biologics Inc - Zoetis Inc For more information visit http://www.researchandmarkets.com/research/s8...cines_skin Source: Plunkett Research Ltd
ZTS: 43.84 (+0.87), RTIX: 5.20 (unch), HALO: 9.34 (+0.31), EBS: 27.64 (+1.28), ANIK: 38.26 (+0.73), MDXG: 11.17 (+0.17)
InsiderInsights.com Daily Round Up 12/11/14: VRX, NS, PSEC, PSX
InsiderInsights - at Seeking Alpha - Thu Dec 11, 11:10PM CST
AMBA: 52.05 (+0.72), PSX: 72.10 (-0.46), CCI: 79.05 (-0.13), VRX: 140.33 (-0.22), RAX: 48.24 (+0.45), SLRC: 18.01 (-0.02), DOOR: 60.04 (-0.10), EBS: 27.64 (+1.28), MMI: 33.68 (+0.05), RLYP: 30.35 (-0.22), FCX: 22.91 (+0.07), NS: 57.17 (+0.24), TTGT: 10.67 (-0.01), GHC: 877.19 (-0.76), WIW: 11.28 (+0.03), ADI: 56.71 (+0.05), HBI: 110.93 (-0.07), SAEX: 4.60 (+0.05), FOXF: 16.15 (+0.07), PSEC: 8.59 (-0.02)
Anthrax - Pipeline Review, H1 2014
M2 - Wed Dec 03, 7:33AM CST
Research and Markets (http://www.researchandmarkets.com/research/gq3s59/anthrax) has announced the addition of the "Anthrax - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Anthrax, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Anthrax and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Anthrax - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Anthrax pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Aradigm - Bavarian Nordic - Bristol-Myers Squibb - Cellceutix - Conkwest - ContraFect - Elusys - Emergent BioSolutions - Evolva - Green Cross - Grifols - Hawaii Biotech - Immunovaccine - Innovative Biologics - MacroGenics - Microbiotix - NanoBio - Navigen - Oragenics - PaxVax - Pfenex - Planet Biotechnology - ProThera Biologics - Protein Potential - PsiOxus - Revivicor - SelectX - Soligenix - Summit - Tetraphase - The Medicines - Vaxin - iBio For more information visit http://www.researchandmarkets.com/research/gq3s59/anthrax
EBS: 27.64 (+1.28), BMY: 59.15 (-0.01)
3 Fast-Growing Biotech Stocks To Buy in December
Todd Campbell, The Motley Fool - Motley Fool - Mon Nov 24, 9:46AM CST
Year end is coming up quickly, and that has investors pouring over portfolios, dissecting financial reports, and considering names to own heading into 2015. With that in mind, read on to learn why I think these three biotech stocks may prove...
INSY: 41.52 (+0.51), EBS: 27.64 (+1.28), CBST: 100.29 (-0.09)
Emergent Biosolutions Earnings Hindsight: Up 9.2% in Last 18 Days (EBS)
Comtex SmarTrend(R) - Mon Nov 24, 8:16AM CST
18 days ago, on November 6th, 2014, Emergent Biosolutions (NYSE:EBS) reported its earnings. Analysts, on average, expected earnings of $0.47 per share on sales of $127.0 million. The company actually reported EPS of $0.50 on sales of $138.0 million, beating EPS estimates by $0.03 and beating revenue estimates by $11.0 million. Shares of Emergent Biosolutions have climbed from $22.49 to $24.56, representing a gain of 9.2% since the company reported earnings 18 days ago.
EBS: 27.64 (+1.28)
Emergent BioSolutions to Webcast Presentation at 25th Annual Oppenheimer Healthcare Conference
GlobeNewswire - Mon Nov 24, 6:00AM CST
Emergent BioSolutions Inc. (NYSE:EBS) announced today that the company will be webcasting its presentation at the 25 Annual Oppenheimer Healthcare Conference in New York on Wednesday, December 10, 2014 at 2:45 PM Eastern. During the presentation, a member of the company's management team will provide a corporate overview, which may include a discussion of the company's recent business developments as well as its most recently reported financial results and guidance. The webcast of this presentation will be available both live and by replay, accessible from the Emergent website www.emergentbiosolutions.com under "Investors."
EBS: 27.64 (+1.28)
Emergent Biosolutions Earnings Hindsight: Up 7.7% in Last 11 Days (EBS)
Comtex SmarTrend(R) - Mon Nov 17, 11:59AM CST
A week ago on November 6th, 2014 Emergent Biosolutions (NYSE:EBS) reported earnings and analysts, on average, expected earnings of $0.47 on sales of $127.0 million. The company actually reported EPS of $0.50 on sales of $138.0 million, beating EPS estimates by $0.03 and beating revenue estimates by $11.0 million. Shares of Emergent Biosolutions have climbed from $22.49 to $24.22, representing a gain of 7.7% since the company reported earnings 11 days ago.
EBS: 27.64 (+1.28)
Worried About a Market Crash? These 3 Stocks Soared During the Great Recession
Todd Campbell, The Motley Fool - Motley Fool - Tue Nov 11, 6:38AM CST
The 7.2% drop in the S&P 500 between mid-September and mid-October was an attention-getting fall that should serve as a wake-up call to investors who may have grown complacent over the past five years, but by historical standards the decline was...
CTRX: 51.83 (+0.14), EBS: 27.64 (+1.28), CMN: 42.07 (+0.40)
Emergent BioSolutions Beats on Q3 Earnings, Guidance Up - Analyst Blog
Lopamudra Bhattacharya - Zacks Investment Research - Mon Nov 10, 11:30AM CST
Emergent BioSolutions reported third quarter earnings of 67 cents per share.
AGN: 210.12 (+0.95), EBS: 27.64 (+1.28), ABAX: 58.48 (+0.22), ABBV: 66.21 (+1.86)
Emergent BioSolutions Seeks Expanded BioThrax Label; Submits FDA Application for Post-Exposure Prophylaxis
GlobeNewswire - Mon Nov 10, 6:07AM CST
Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking to expand the label of BioThrax (Anthrax Vaccine Adsorbed) to include a post-exposure prophylaxis (PEP) indication. BioThrax, the only FDA-licensed vaccine to prevent anthrax disease, is currently licensed for a pre-exposure prophylaxis indication only.
EBS: 27.64 (+1.28)
Emergent Biosolutions posts 3Q profit
Automated Insights - Fri Nov 07, 4:04AM CST
ROCKVILLE, Md. (AP) _ Emergent Biosolutions Inc. (EBS) on Friday reported earnings of $21.8 million in its third quarter.
EBS: 27.64 (+1.28)
Emergent BioSolutions Inc Busts Through Guidance. Sort of.
Brian Orelli, The Motley Fool - Motley Fool - Thu Nov 06, 7:39PM CST
Considering that Emergent BioSolutions has regular government contracts and other manufacturing contracts -- so regular that it's willing to give quarterly guidance, which many companies wouldn't dream of -- it was a little surprising to see by...
EBS: 27.64 (+1.28)
